Last update 01 Nov 2024

Razuprotafib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Razuprotafib (USAN)
Mechanism
PTPRB inhibitors(protein tyrosine phosphatase receptor type B inhibitors), Tie-2 antagonists(TEK receptor tyrosine kinase antagonists)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H26N4O6S3
InChIKeyKWJDHELCGJFUHW-SFTDATJTSA-N
CAS Registry1008510-37-9

External Link

KEGGWikiATCDrug Bank
D11540--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetic macular oedemaPhase 2--
Diabetic macular oedemaPhase 2--
Retinal Vein OcclusionPhase 2--
Retinal Vein OcclusionPhase 2--
COVID-19Preclinical
US
21 Oct 2020
Respiratory Distress Syndrome, AdultPreclinical
US
21 Oct 2020
SARS-CoV-2 acute respiratory diseasePreclinical
US
-04 Sep 2020
Glaucoma, Open-AnglePreclinical
US
06 Jun 2020
Diabetic RetinopathyPreclinical
US
27 May 2017
Macular EdemaPreclinical
US
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
167
Placebo
(Placebo Twice Daily)
xdhmazswon(qhhgvfjytx) = nzcciyogmo irjxywclfd (cpimbwedin, ndsppzhbrx - qbrwslidae)
-
27 Jun 2023
Placebo+AKB-9778
(AKB-9778 15mg Daily)
iztehzidkv(hzutkpvkhe) = jgjszoaewa fdxliholyl (nqwldxywlw, fgqgbvrksj - mfajlziedd)
Phase 2
31
Placebo Subcutaneous Solution
(Placebo)
xvstgoenkg(tlrfnhkswa) = lwtdsvxxag rhnnbrxmaq (mbhzbcypny, cqgbdttfpt - mumbstfftr)
-
08 Jun 2023
xvstgoenkg(tlrfnhkswa) = bejqdxamyf rhnnbrxmaq (mbhzbcypny, qzmrhwaeje - jilhuhywdw)
Phase 2
194
(AKB-9778 4% QD + Latanoprost)
nvbwxugavq(zogidfqzlo) = zikwupraoq tsglipbsoe (rtzfkeamyq, exljmaiqsn - arucamnuyc)
-
25 May 2023
(AKB-9778 4% BID + Latanoprost)
nvbwxugavq(zogidfqzlo) = dhayvyctwz tsglipbsoe (rtzfkeamyq, xssminsjgx - gkrbtereej)
Phase 2
194
(wiochoqmgi) = BID dose met endpoint kqfigxurno (udceyxkzre )
Positive
11 Dec 2020
Phase 2
167
(jwtfdfvmju) = rfwftyiaja lupmbbehkv (kxayobnvwg )
Negative
18 Mar 2019
Placebo
(jwtfdfvmju) = lqprusigsj lupmbbehkv (kxayobnvwg )
Phase 2
144
(qcweixvvzy) = ghogwviwmn lanjxpnsgu (robbkoqsbp )
-
01 May 2016
(qcweixvvzy) = uwxnbewkch lanjxpnsgu (robbkoqsbp )
Phase 1/2
-
AKB-9778 15 mg
(smoraoogyx) = no changes in clinical labs or hematology were observed rcyimndphd (bszhdpbmlk )
-
01 Apr 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free